The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin

NCT04601077 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

524

Enrollment

INDUSTRY

Sponsor class

Stopped The study stopped due to futility.

Conditions

COVID-19

Interventions

DRUG: Nitric Oxide lozenges, 30 mg
DRUG: Placebo

Sponsor

Nitric Oxide Innovations LLC